Mutlu_2011_Drug.Dev.Ind.Pharm_37

Reference

Title : New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations - Mutlu_2011_Drug.Dev.Ind.Pharm_37_775

Author(s) : Mutlu NB , Degim Z , Yilmaz S , Essiz D , Nacar A

Ref : Drug Dev Ind Pharm , 37 :775 , 2011

Abstract : The aim of this study was to determine the transportations of rivastigmine containing from various liposome formulations through Madin Darby Canine Kidney (MDCK) cells monolayer and to compare the in vitro test results with in vivo. There is no other liposome formulation of rivastigmine and the transportations of rivastigmine through MDCK cell monolayers or related study available in the literature. Cytotoxicity (MTT) test was used to determine cell viabilities. The effect of sodium-taurocholate or dimethyl-beta-cyclodextrine as penetration enhancer was also investigated. Characterization and stability studies for liposome formulations were performed. Permeation experiments of rivastigmine were performed through MDCK cells and dialysis membrane. The kinetic of release from liposomes was also investigated. The highest apparent permeability coefficient (log. values) was obtained with sodium-taurocholate liposomes for -1.15 +/- 0.16 for MDCK cell. Rivastigmine liposomes and solutions were also administered to mice orally and intraperitonally. Acetylcholinesterase (AChE) activity was determined by Ellman method. AChE% inhibition values were calculated for both blood and brain after administration of rivastigmine solution and liposomes. The highest AChE inhibition was observed for rivastigmine-sodium-taurocholate liposomes. Histological observations of the mice' brains were performed under transmission electron microscope (TEM). The histological results were also indicated and supported all these findings.

ESTHER : Mutlu_2011_Drug.Dev.Ind.Pharm_37_775

PubMedSearch : Mutlu_2011_Drug.Dev.Ind.Pharm_37_775

PubMedID: 21231901

Mutlu_2011_Drug.Dev.Ind.Pharm_37_775

Reference

Related information

Citations formats